Efipladib

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameEfipladib
Drug Alias Nameefipladibum艾非拉地efipladib依非拉迪PLA-902
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytosolic phospholipase A2 inhibitors
TargetsCytosolic phospholipase A2
Therapy Area/IndicationsOsteoarthritisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsOsteoarthritisArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksKEGG